

Pathways of the Heart

Rahul C. Deo, MD, PhD; Frederick P. Roth, PhD

Disease heterogeneity presents a formidable challenge for clinical medicine. We are unlikely to develop successful, targeted treatments unless diagnostic schemes begin to reflect the biological complexity underlying superficially similar disease phenotypes. To address heterogeneity, there is an increasing recognition that realistic disease models need to be built on a foundation of quantitative molecular information.¹ Such a “systems medicine” approach should ultimately allow classification into biologically more homogeneous groups, with similar prognosis and treatment response.

Article see p 371

Oncology has been among the first specialties to embrace molecular profiling to improve clinical decision making. Today, a wealth of expression profiling information exists for tumors, and early efforts are being made to classify patients into likely treatment responders for specific chemotherapeutics.² The investigation of complex multisystem pathologies, such as cardiovascular disease, has been slower to incorporate molecular profiling, in part, because of the involvement of multiple tissues, many of which are not readily accessible. Moreover, cardiovascular disease, unlike cancer, is not clonal in origin, making experimental analyses more challenging. It is clear, however, that broadly defined diseases such as the cardiomyopathies are the product of diverse genetic and environmental agents³; one can expect that quantitative molecular profiling will shed light on distinct, pathological activities underlying these conditions, thus allowing more meaningful classification schemes beyond those that are solely based on anatomic or hemodynamic considerations.

The article by Barth et al⁴ in this issue of *Circulation: Cardiovascular Genetics* represents such a broadened search for molecular correlates of cardiovascular disease. The authors focus on the problem of heart failure with mechanical dyssynchrony (DHF) and its treatment by cardiac resynchronization therapy (CRT). Clinically, CRT has been a remarkable success, with significant gains in quality of life and mortality.⁵ Multiple studies have investigated the physiological consequences of dyssynchrony and the improvements resulting from CRT; however, the underlying molecular processes largely remain unclear. This study is unique in its

use of DNA microarrays to ask whether heterogeneity resulting from DHF and the physiological benefits from CRT are broadly reflected at a molecular level.

DNA microarrays allow scientists to simultaneously survey the expression level of thousands of mRNAs under a variety of experimental conditions. A key strength of microarray technology is that it is inherently free of inspection or ascertainment biases—a “transcriptome-wide” approach does not require preconceived notions of which biological processes are important. Unbiased approaches, including genome-wide association and metabolomics studies, have the potential to lead us to entirely unexpected disease mechanisms. However, large-scale (‘omic) data presents analysis challenges of its own—requiring an understanding of measurement error, detection limits, and problems that arise when a plethora (sometimes thousands) of hypotheses are tested. Any of these issues can lead to erroneous conclusions and compromise the generalizability of the results. Fortunately, bioinformatics research has focused on these issues for more than a decade, and many solutions have become available.

Armed with ‘omic data sets and bioinformatics tools, Barth et al tackle the hypothesis that CRT reduces the regional heterogeneity in gene expression induced by DHF. The experimental design (Figure) features 3 groups:

1. DHF: produced by experimental left bundle-branch block followed by rapid, sustained right atrial pacing.
2. CRT: produced by synchronized biventricular pacing of the DHF model (at the same rate as atrial pacing in DHF).
3. NF: normal controls.

Tissue samples from the anterior and lateral segments of the left ventricle of each dog were subjected to microarray




Figure. Experimental design of Barth et al. For clarity, some analytic comparisons have been omitted. r indicates right; ant, anterior; lat, lateral).

The opinions expressed in this article are not necessarily those of the editors or the American Heart Association.

From the Department of Biological Chemistry and Molecular Pharmacology (R.C.D., F.P.R.), Harvard Medical School; and Cardiology Division (R.C.D.), Massachusetts General Hospital, Boston, Massachusetts.

Correspondence to Rahul C. Deo, MD, PhD, Harvard Medical School, Boston, MA 02115. E-mail rdeo@partners.org

(*Circ Cardiovasc Genet.* 2009;2:303-305.)

© 2009 American Heart Association, Inc.

Circ Cardiovasc Genet is available at
<http://circgenetics.ahajournals.org>
 DOI: 10.1161/CIRCGENETICS.109.892588

profiling, and comparisons were made within and across groups. Bioinformatics methods, including pathway enrichment analysis and hierarchical clustering, were used to analyze the microarray data. Each of these will be discussed.

Pathway Enrichment Analysis

Typical 'omics experiments generate lists of significantly changed genes, proteins, or metabolites. In the usual microarray experiment, these lists include hundreds of genes, only a handful of which are well known to a given experimenter. It is difficult for the researcher to see the forest for the trees in a long list of changed genes, a problem exacerbated by the fact that nearly every method in experimental molecular biology yields a mixture of true and spurious results. Because the usual goal of such experiments is to understand what biological processes differentiate the groups under comparison, new analytic techniques were required. Pathway analysis has emerged as such a tool.

Many properties are known or measured for genes and their encoded mRNAs and protein products, including tissue expression patterns, interactions partners, and molecular functions. Systematic efforts have been made to compile such properties into databases, with a vocabulary of gene ontology (GO) terms (<http://www.geneontology.org/>) being the most widely used. Both automated and manual efforts have annotated genes with GO terms in dozens of organisms. GO terms cover a range of gene properties, including cellular location (eg, mitochondria), molecular function (eg, transcription factor), and involvement in biological processes (eg, apoptosis). Related to biological processes, biological pathways comprise groups of genes that participate toward a common cellular function such as "oxidative phosphorylation." The Kyoto Encyclopedia of Genes and Genomes is a commonly used database of biological pathways and currently contains hundreds of groupings of genes (<http://www.genome.jp/kegg/pathway.html>).

This wealth of information defines many "gene sets" and we can ask whether a "query list" of changed genes from a microarray experiment shares significant similarity with any of these sets. A number of software packages have been designed to perform this type of analysis. These broadly differ by the statistic used to measure enrichment of a gene property within a query gene list and the method used to determine statistical significance. In this article, Barth et al use 2 such packages: FatiGO (<http://babelomics.bioinfo.cipf.es/EntryPoint?loadForm=fatigo>) and gene set analysis (<http://www-stat.stanford.edu/~tibs/GSA/>), which illustrate 2 categories of pathway enrichment analysis.

FatiGO, FuncAssociate,⁶ and several other applications use the hypergeometric test as a measure of how well one's query list overlaps with each predefined gene set. The relevant analytic parameters include the number of total genes in the "universe" to be considered (in this case, all the genes on the microarray), the number of genes in the query list, the number of universe genes corresponding to the gene set of interest, and the number of genes in the query list corresponding to that same gene set. Fisher Exact Test is used to calculate a *P* value measuring significance of the overlap. For example, if the canine microarray includes 20 000 genes, 500 of which

correspond to the pathway oxidative phosphorylation and your query list of 100 genes includes 10 genes corresponding to the same pathway, your query list would be significantly enriched for oxidative phosphorylation ($P=0.0002$).

A caveat to this analysis is the fact that one is often testing one's gene list against hundreds of pathways or thousands of GO terms. Clearly, low *P* values will arise simply by chance and some correction for multiple hypothesis testing is essential. Simple Bonferroni approaches are often applied, but these incorrectly assume that GO terms are independent and are therefore unnecessarily conservative. FatiGO outputs an adjusted *P* value for several methods of false-discovery rate estimation. FatiGo uses the well-known Benjamini-Hochberg method to estimate the false-discovery rate. Alternatively, both FatiGO and FuncAssociate use resampling-based testing to develop the distribution of Fisher exact test results for many GO terms under the null hypothesis. In this case, the label "in the query list" and "not in the query list" are permuted randomly among the genes in the universe and an enrichment *P* value is computed for overlap of the random query list with each gene set. In principle, FatiGO and FuncAssociate can be used to find any type of overrepresented gene property, such as promoter elements and protein domains. Many packages allow you to supply your own annotations for other types of 'omic data; the results of the analyses (including those using GO terms or Kyoto Encyclopedia of Genes and Genomes pathways) will, of course, depend on the completeness and quality of the annotations.

A second general approach to pathway enrichment is used in Gene Set Enrichment Analysis (<http://www.broad.mit.edu/gsea>) and gene set analysis. In these packages, a statistic is computed for each gene set that captures the degree to which genes in the set are statistical outliers in the experimental microarray comparison data. The null distribution for each statistic is generated by permuting the class labels for each microarray (eg, shuffling case and control status) and/or the gene membership of the various gene sets.

In this article, Barth et al use the FatiGO tool to evaluate pathway enrichment in the list of the significantly changed genes in their comparison of the anterior wall (DHF versus NF) and find multiple overrepresented pathways, including metabolic (eg, oxidative phosphorylation) and signaling pathways (eg, Wnt and vascular endothelial growth factor). The pathways listed are consistent across at least 2 experiments, reinforcing their validity. The utility of an enriched pathway or GO term, of course, depends on whether it can motivate a testable hypothesis. For example, knowing that a specific kinase pathway seems to be activated might lead one to evaluate the biological effects of specific kinase inhibitors. Enrichment for vague pathways may not represent an immediately testable hypothesis.

In addition to identifying underlying biological processes in a set of changed genes, pathway analysis can be used to compare different microarray experiments for "biological similarity." Pathway-based comparisons can be used to test the generalizability of one's results (as performed by Barth et al) or to search for other perturbations that are similar to the one under consideration (a pathway "signature").⁷ When performing comparisons, one should choose a quantitative

measure for comparison that allows establishment of statistical significance. Many measures are “nonclassical” in that they lack established null distributions, but resampling can generate empirical distributions of the measure and enable one to estimate whether the observed similarity is significant. Typically, such pathway-focused analyses base comparisons on normalized gene expression values for genes in the pathway,⁸ or, if case-control experiments are to be compared, a fold-change value or *t*-statistic is used for individual genes.⁷

Hierarchical Clustering

A key conclusion of the Barth et al article is that CRT reduces the heterogeneity in gene expression across the left ventricle introduced by dyssynchronous heart failure. If so, CRT hearts would more closely resemble NF than DHF hearts. As one method to evaluate this hypothesis, the authors use hierarchical clustering to look for natural groupings of NF, DHF, and CRT microarray samples. Hierarchical clustering is a powerful, potentially unbiased method of looking for similarities among experimental samples.⁹ It has been applied successfully to microarray data to identify genomic features of cancers that predict mortality and chemotherapy response¹⁰ and to identify likely gene targets for established drugs.¹¹ All forms of clustering require a metric for comparison (usually Euclidean Distance or some type of correlation coefficient) and a method of grouping similar samples. Hierarchical clustering works by first clustering the most similar samples and then successively grouping small clusters into larger ones.

Hierarchical clustering is unbiased only when clustering is performed across all genes in the array. However, there are many potential sources of both technical and biological variance in microarray analysis that are unrelated to the biological differences of interest, and it is notoriously difficult to cluster biological samples. In a *tour de force* microarray analysis of 300 genetic and experimental perturbations in yeast, Hughes et al¹¹ accounted for the intrinsic variability of genes in 63 control samples to greatly improve clustering ability. For practical reasons, most microarray studies (mammalian or otherwise) have not included the large number of control samples needed to establish baseline variance for each gene. As one solution, in a large series of cancer profiling experiments, Brown and coworkers¹⁰ limited cluster analysis to those “interesting” genes showing a 2-fold deviation from background in some minimum fraction ($\approx 10\%$ to 15%) of microarrays. In the study by Barth et al, hierarchical clustering was limited to a subset of genes identified by ANOVA to discriminate among the 3 comparison groups. This method seems to have selected hundreds of genes that discriminated NF from DHF and very few distinguishing NF from CRT, such that pairwise similarity measures and thus clustering results were likely dominated by the preponderance of genes that discriminate between NF and DHF. Failure of a gene to discriminate between 2 samples may stem from biological similarity between 2 samples or, alternatively, can arise if the gene is one or both samples highly variable, leading to reduced power to detect significant differences. In either case, clustering based on this gene subset showed NF and CRT

groups to be indistinguishable and found both to be markedly different from DHF. Although promising in support of the hypothesis that CRT regularizes heterogeneity in ventricular gene expression, it will be important to see whether this observation extends over a broader set of genes.

Conclusions

Although CRT has proven remarkably successful in treating heart failure patients, up to a quarter of individuals still fail to respond.⁵ Well-designed microarray experiments along with rigorous bioinformatics analyses may identify biological pathways that remain dysregulated even after CRT, and thus could be targeted by adjunct pharmacological therapy. Such a discovery would truly represent a triumph for a systems medicine approach to complex, cardiovascular disease.

Sources of Funding

Dr Deo was supported by National Institutes of Health grant T32 HL007208. Dr Roth was supported by National Institutes of Health grants HL081341, HG004233, HG0017115, NS035611, and HG003224 and by the Canadian Institute for Advanced Research.

Disclosures

None.

References

- Loscalzo J, Kohane I, Barabasi AL. Human disease classification in the postgenomic era: a complex systems approach to human pathobiology. *Mol Syst Biol.* 2007;3:124.
- Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, Cragun J, Cottrill H, Kelley MJ, Petersen R, Harpole D, Marks J, Berchuck A, Ginsburg GS, Febbo P, Lancaster J, Nevins JR. Genomic signatures to guide the use of chemotherapeutics. *Nat Med.* 2006;12:1294–1300.
- Seidman JG, Seidman C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. *Cell.* 2001;104:557–567.
- Barth AS, Aiba T, Halperin V, DiSilvestre D, Chakir K, Colantuoni C, Tunin RS, Dimaano VL, Yu W, Abraham MR, Peltonen L. Cardiac resynchronization therapy corrects dyssynchrony-induced regional gene expression changes on a genomic level. *Circ Cardiovasc Genet.* 2009;2:371–378.
- Hasan A, Abraham WT. Cardiac resynchronization treatment of heart failure. *Annu Rev Med.* 2007;58:63–74.
- Berriz GF, King OD, Bryant B, Sander C, Roth FP. Characterizing gene sets with FuncAssociate. *Bioinformatics.* 2003;19:2502–2504.
- Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander ES, Golub TR. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. *Science.* 2006;313:1929–1935.
- Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, Olson JA Jr, Marks JR, Dressman HK, West M, Nevins JR. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. *Nature.* 2006;439:353–357.
- Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. *Proc Natl Acad Sci USA.* 1998;95:14863–14868.
- Bohen SP, Troyanskaya OG, Alter O, Warnke R, Botstein D, Brown PO, Levy R. Variation in gene expression patterns in follicular lymphoma and the response to rituximab. *Proc Natl Acad Sci USA.* 2003;100:1926–1930.
- Hughes TR, Marton MJ, Jones AR, Roberts CJ, Stoughton R, Armour CD, Bennett HA, Coffey E, Dai H, He YD, Kidd MJ, King AM, Meyer MR, Slade D, Lum PY, Stepaniants SB, Shoemaker DD, Gachotte D, Chakraburty K, Simon J, Bard M, Friend SH. Functional discovery via a compendium of expression profiles. *Cell.* 2000;102:109–126.